rais estim opdivo earn
action rais estim ono pharmaceut increas
target price potenti return maintain
invest overview rais earn estim reflect higher
opdivo royalti revenu us compani merck make chang
estim opdivo sale japan opdivo appear struggl
versu rival drug keytruda non-smal cell lung cancer nsclc
indic see room opdivo sale growth drug
immun checkpoint inhibitor approv gastric cancer indic
also approv malign pleural mesothelioma mpm august
royalti paid merck intellectu properti compens
look like break mark increas earn
contribut opdivo
risk opdivo drug price cut effect
novemb price cut implement follow chang dosag
administr method flat dose everi two week
expect major impact actual sale although
investor take note potenti near-term risk tecentriq anoth
checkpoint inhibitor launch japan think opdivo
market could switch defens strategi nsclc
valuat chang base year valuat metric
set tp assum twelve-month forward price-to-earnings previous
appli ep
valuat metric
chang tp
number share mn
price month
price rel chart measur perform
topix close
spot exchang rate
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
price upsid rate outperform target price analyst fumiyoshi
profit tax
issuanc retir stock
net chang cash
number share mn
incom expens
profit tax
cash equival
royalti bm
charl martineau univers toronto figur opdivo estim number newli prescrib patient
head neck cancer
figur number cancer patient
nonmelanoma skin
melanoma skin
compil ono pharma base globocan
compani mention price
